In vivo regulation of chemokine activity by post-translational modification

Immunology and Cell Biology

Volumn 91, Issue 6, 2013, Pages 402-407

  Moelants, Eva A V ^a   Mortier, Anneleen ^a   Van Damme, Jo ^a   Proost, Paul ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

biological activity; chemokines; in vivo; post translational modification; regulation

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE; FRACTALKINE;

CELL MIGRATION; HUMAN; IN VIVO STUDY; MACROPHAGE; NEUTROPHIL; NONHUMAN; PROTEIN PROCESSING; REVIEW;

ANIMALS; ARTHRITIS, RHEUMATOID; CHEMOKINES; HUMANS; HYDROLASES; IMMUNOMODULATION; PEPTIDE HYDROLASES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84879845418     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.16     Document Type: Review

References (76)

1. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928. (Pubitemid 38680444)
2. Nomiyama H, Osada N, Yoshie O. The evolution of mammalian chemokine genes. Cytokine Growth Factor Rev 2010; 21: 253-262.
3. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front Biosci 2009; 14: 540-551.
4. Proost P, Vynckier AK, Mahieu F, Put W, Grillet B, Struyf S et al. Microbial toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur J Immunol 2003; 33: 3146-3153. (Pubitemid 37428347)
5. Loos T, Dekeyzer L, Struyf S, Schutyser E, Gijsbers K, Gouwy M et al. TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. Lab Invest 2006; 86: 902-916. (Pubitemid 44268165)
6. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-176. (Pubitemid 30127598)
7. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127. (Pubitemid 30398626)
8. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity 2012; 36: 705-716.
9. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 593-609. (Pubitemid 41505519)
10. Mortier A, Van Damme J, Proost P. Overview of the mechanisms regulating chemokine activity and availability. Immunol Lett 2012; 145: 2-9.
11. Gouwy M, Schiraldi M, Struyf S, Van Damme J, Uguccioni M. Possible mechanisms involved in chemokine synergy fine tuning the inflammatory response. Immunol Lett 2012; 145: 10-14.
12. Hansell CA, Hurson CE, Nibbs RJ. DARC vand D6: silent partners in chemokine regulation? Immunol Cell Biol 2011; 89: 197-206.
13. Proudfoot AE. The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans 2006; 34: 422-426. (Pubitemid 43954002)
14. Kim Y, Lee S, Kim S, Kim D, Ahn JH, Ahn K. Human cytomegalovirus clinical strainspecific microRNA miR-UL148D targets the human chemokine RANTES during infection. PLoS Pathog 2012; 8: e1002577.
15. Tano N, Kim HW, Ashraf M. microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. PLoS One 2011; 6: e23114.
16. van Solingen C, de Boer HC, Bijkerk R, Monge M, van Oeveren-Rietdijk AM, Seghers L et al. MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca- 1(+)/Lin(-) progenitor cells in ischaemia. Cardiovasc Res 2011; 92: 449-455.
17. Mortier A, Van Damme J, Proost P. Regulation of chemokine activity by posttranslational modification. Pharmacol Ther 2008; 120: 197-217.
18. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96: 2673-2681.
19. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 2000; 96: 1674-1680. (Pubitemid 30662110)
20. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 289: 1202-1206. (Pubitemid 30650734)
21. Struyf S, Proost P, Schols D, De Clercq E, Opdenakker G, Lenaerts JP et al. CD26/ dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999; 162: 4903-4909. (Pubitemid 29314895)
22. Malkowski MG, Lazar JB, Johnson PH, Edwards BF. The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence. J Mol Biol 1997; 266: 367-380. (Pubitemid 27171021)
23. Schulz-Knappe P, Magert HJ, Dewald B, Meyer M, Cetin Y, Kubbies M et al. HCC-1, a novel chemokine from human plasma. J Exp Med 1996; 183: 295-299. (Pubitemid 26028770)
24. Detheux M, Standker L, Vakili J, Munch J, Forssmann U, Adermann K et al. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J Exp Med 2000; 192: 1501-1508.
25. Mortier A, Loos T, Gouwy M, Ronsse I, Van Damme J, Proost P. Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine deiminases (PAD) differently affects its biological activity. J Biol Chem 2010; 285: 29750-29759.
26. Proost P, Loos T, Mortier A, Schutyser E, Gouwy M, Noppen S et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med 2008; 205: 2085-2097.
27. Moelants EAV, Mortier A, Van Damme J, Proost P, Loos T. Peptidylarginine deiminases: role in physiology, inflammation and pathology. Drug Discovery Today: Technologies 2012; 9: e261-e280.
28. Jiang Y, Tabak LA, Valente AJ, Graves DT. Initial characterization of the carbohydrate structure of MCP-1. Biochem Biophys Res Commun 1991; 178: 1400-1404.
29. Proost P, Mahieu F, Schutyser E, Van Damme J. Posttranslational processing of chemokines. Methods Mol Biol 2004; 239: 27-44.
30. Durkan AM, Alexander RT, Liu GY, Rui M, Femia G, Robinson LA. Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells. J Am Soc Nephrol 2007; 18: 74-83. (Pubitemid 46053424)
31. Molon B, Ugel S, Del PF, Soldani C, Zilio S, Avella D et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208: 1949-1962.
32. Lee JR, Kim JK, Lee SJ, Kim KP. Role of protein tyrosine nitration in neurodegenerative diseases and atherosclerosis. Arch Pharm Res 2009; 32: 1109-1118.
33. Tester AM, Cox JH, Connor AR, Starr AE, Dean RA, Puente XS et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS One 2007; 2: e312.
34. Schroder JM, Mrowietz U, Morita E, Christophers E. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. J Immunol 1987; 139: 3474-3483. (Pubitemid 18022004)
35. Yoshimura T, Matsushima K, Oppenheim JJ, Leonard EJ. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J Immunol 1987; 139: 788-793. (Pubitemid 17107077)
36. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987; 84: 9233-9237.
37. Van Damme J, Van Beeumen J, Opdenakker G, Billiau A. A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity. J Exp Med 1988; 167: 1364-1376.
38. Schroder JM, Gregory H, Young J, Christophers E. Neutrophil-activating proteins in psoriasis. J Invest Dermatol 1992; 98: 241-247.
39. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002; 277: 24584-24593. (Pubitemid 34951986)
40. Rhode A, Pauza ME, Barral AM, Rodrigo E, Oldstone MB, von Herrath MG et al. Isletspecific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 2005; 175: 3516-3524. (Pubitemid 41292009)
41. Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K et al. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. Int J Oncol 2012; 40: 560-566.
42. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98: 3554-3561.
43. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011; 121: 308-317.
44. Casrouge A, Bisiaux A, Stephen L, Schmolz M, Mapes J, Pfister C et al. Discrimination of agonist and antagonist forms of CXCL10 in biological samples. Clin Exp Immunol 2012; 167: 137-148.
45. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997; 185: 111-120. (Pubitemid 27039446)
46. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromalderived factor-1alpha. Am J Pathol 1999; 154: 1125-1135. (Pubitemid 29169747)
47. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 1995; 28: 495-500.
48. De La Luz SM, Yang F, Narazaki M, Salvucci O, Davis D, Yarchoan R et al. Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood 2004; 103: 2452-2459. (Pubitemid 38392993)
49. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP et al. Processing by CD26/ dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromalcell- derived factor-1alpha. FEBS Lett 1998; 432: 73-76. (Pubitemid 28360743)
50. Davis DA, Singer KE, De La Luz SM, Narazaki M, Yang F, Fales HM et al. Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1alpha in the circulation. Blood 2005; 105: 4561-4568. (Pubitemid 40807271)
51. Vergote D, Butler GS, Ooms M, Cox JH, Silva C, Hollenberg MD et al. Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegeneration. Proc Natl Acad Sci USA 2006; 103: 19182-19187. (Pubitemid 350002847)
52. Cho SY, Xu M, Roboz J, Lu M, Mascarenhas J, Hoffman R. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res 2010; 70: 3402-3410.
53. Ludwig A, Weber C. Transmembrane chemokines: versatile 'special agents' in vascular inflammation. Thromb Haemost 2007; 97: 694-703. (Pubitemid 46779956)
54. Ruth JH, Haas CS, Park CC, Amin MA, Martinez RJ, Haines GK III et al. CXCL16- mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006; 54: 765-778.
55. Ueland T, Smedbakken LM, Hallen J, Atar D, Januzzi JL, Halvorsen B et al. Soluble CXCL16 and long-term outcome in acute ischemic stroke. Atherosclerosis 2012; 220: 244-249.
56. Matsushita K, Toiyama Y, Tanaka K, Saigusa S, Hiro J, Uchida K et al. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol 2012; 19 (Suppl 3), S518-S527.
57. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001; 7: 285-289. (Pubitemid 32183031)
58. Krensky AM, Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol 2007; 3: 164-170. (Pubitemid 46327139)
59. Oran PE, Sherma ND, Borges CR, Jarvis JW, Nelson RW. Intrapersonal and populational heterogeneity of the chemokine RANTES. Clin Chem 2010; 56: 1432-1441.
60. Lim JK, Burns JM, Lu W, DeVico AL. Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5. J Leukoc Biol 2005; 78: 442-452. (Pubitemid 41061316)
61. Struyf S, De M,I, Scharpe S, Lenaerts JP, Menten P, Wang JM et al. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol 1998; 28: 1262-1271. (Pubitemid 28156417)
62. Schols D, Proost P, Struyf S, Wuyts A, De Meester I, Scharpe S et al. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 1998; 39: 175-187. (Pubitemid 28495573)
63. Opdenakker G, Froyen G, Fiten P, Proost P, Van Damme J. Human monocyte chemotactic protein-3 (MCP-3): molecular cloning of the cDNA and comparison with other chemokines. Biochem Biophys Res Commun 1993; 191: 535-542. (Pubitemid 23222669)
64. Van Damme J, Proost P, Lenaerts JP, Opdenakker G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992; 176: 59-65.
65. Menten P, Wuyts A, Van Damme J. Monocyte chemotactic protein-3. Eur Cytokine Netw 2001; 12: 554-560. (Pubitemid 34062141)
66. Forssmann U, Magert HJ, Adermann K, Escher SE, Forssmann WG, Hemofiltrate CC. Chemokines with unique biochemical properties: HCC-1/CCL14a and HCC-2/CCL15. J Leukoc Biol 2001; 70: 357-366. (Pubitemid 32826122)
67. Richter R, Schulz-Knappe P, John H, Forssmann WG. Posttranslationally processed forms of the human chemokine HCC-1. Biochemistry 2000; 39: 10799-10805.
68. Munch J, Standker L, Pohlmann S, Baribaud F, Papkalla A, Rosorius O et al. Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages. Antimicrob Agents Chemother 2002; 46: 982-990. (Pubitemid 34260340)
69. Vakili J, Standker L, Detheux M, Vassart G, Forssmann WG, Parmentier M. Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active. J Immunol 2001; 167: 3406-3413. (Pubitemid 32852585)
70. Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ. Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 2005; 174: 7341-7351. (Pubitemid 40705704)
71. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102: 1186-1195. (Pubitemid 36988021)
72. Damas JK, Boullier A, Waehre T, Smith C, Sandberg WJ, Green S et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005; 25: 2567-2572. (Pubitemid 43732280)
73. Rimaniol AC, Till SJ, Garcia G, Capel F, Godot V, Balabanian K et al. The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol 2003; 112: 1139-1146. (Pubitemid 37550007)
74. Sporer B, Kastenbauer S, Koedel U, Arendt G, Pfister HW. Increased intrathecal release of soluble fractalkine in HIV-infected patients. AIDS Res Hum Retroviruses 2003; 19: 111-116. (Pubitemid 36308048)
75. Kastenbauer S, Koedel U, Wick M, Kieseier BC, Hartung HP, Pfister HW. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol 2003; 137: 210-217. (Pubitemid 36355942)
76. Ruth JH, Volin MV, Haines GK III, Woodruff DC, Katschke KJ Jr., Woods JM et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001; 44: 1568-1581. (Pubitemid 32642219)